Alector (ALEC)
(Delayed Data from NSDQ)
$3.03 USD
-0.10 (-3.19%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.04 +0.01 (0.33%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Alector, Inc. has a PEG ratio of 0.48 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.48.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALEC 3.03 -0.10(-3.19%)
Will ALEC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALEC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALEC
Lifecore Biomedical (LFCR) Soars 10.8%: Is Further Upside Left in the Stock?
After Golden Cross, Alector (ALEC)'s Technical Outlook is Bright
ALEC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates
Other News for ALEC
ALEC forms MACD Bullish Signal Line Cross on September 18
The technical outlook for ALEC is unchanged after it rises 6.88% on September 17
MACD Bearish Signal Line Cross appears for ALEC after 6.76% move
ALEC forms 180 Bullish Setup on September 15
The technical outlook for ALEC is unchanged after it falls 4.18% on September 12